Search results
Results from the WOW.Com Content Network
Puma SE is a German multinational corporation who design and manufacture athletic and casual footwear, ... As of July 2007, PPR owned over 60% of Puma stock. [36]
Puma Biotech (PBYI) beats earnings and revenue estimates in second-quarter 2022. PBYI's stock surges at market close following the news.
Puma Biotech (PBYI) incurs wider loss in Q2. Sales of Nerlynx improve from first-quarter levels. Stock rises 23%.
The stock of Puma SE (OTCPK:PUMSY, 30-year Financials) appears to be significantly overvalued, according to GuruFocus Value calculation.
Puma was founded in September 2010 by Alan Auerbach to identify and in-license compounds that were already in clinical development. [2] This was the same business plan Auerbach had followed at Cougar Biotechnology, which he founded in 2003, and through which he in-licensed abiraterone acetate from BTG plc. [2]
On March 24, 1999, New Regency executive David Matalon joined the supervisory board of Puma AG, an international sports company. At the time, Regency was the largest single shareholder in Puma, with more than a 25% stake. [6] Arnon Milchan also owned Puma stock, which he later sold for $676 million in May 2003. [7]
Puma Biotech (PBYI) betters loss estimates in Q3. However, its only marketed drug, Nerlynx, disappoints with low sequential growth and as a result, shares take a hit.
Discover the latest breaking news in the U.S. and around the world — politics, weather, entertainment, lifestyle, finance, sports and much more.